

**Remarks**

Applicants submit the following amendments and remarks in response to the final office action mailed on April 12, 2007, setting a period for response, which expires July 12, 2007. Accordingly, this response is timely filed.

Claims 20-23 are pending in this application.

**Double Patenting Rejection**

Claims 20-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 2 of U.S. Patent No. 6,977,302. The Examiner contended that a timely filing of a Terminal Disclaimer in compliance with 37 CFR 1.231(c) or 1.321(d) will remove the rejection based on nonstatutory double patenting.

Without agreeing or disagreeing with the Examiner and in order to expedite prosecution, Applicants herein submit a Terminal Disclaimer and request that the Examiner withdraws her double patenting rejection and allows Claims 20-23.

Respectfully submitted,

Date: June 5, 2007

/Elsa Djuardi/  
Elsa Djuardi, Ph.D.  
Attorney for Applicants  
Reg. No. 45,963

Pfizer Inc.  
Patent Dept.  
10555 Science Center Drive  
San Diego, CA 92121  
Tel: (858) 638-6117  
Fax: (858) 678-8233